Gilead Sciences Inc. (GILD) EVP Gregg H. Alton Sells 5,000 Shares of Stock
Gilead Sciences Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the transaction, the executive vice president now directly owns 132,964 shares of the company’s stock, valued at approximately $10,881,773.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) opened at 79.25 on Wednesday. Gilead Sciences Inc. has a 52 week low of $76.67 and a 52 week high of $111.11. The firm has a 50-day moving average of $79.45 and a 200 day moving average of $85.72. The company has a market cap of $104.58 billion, a P/E ratio of 6.96 and a beta of 1.06.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same period last year, the firm earned $3.15 EPS. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.37%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 16.56%.
Institutional investors have recently added to or reduced their stakes in the stock. Franklin Street Advisors Inc. NC raised its position in Gilead Sciences by 6.2% in the first quarter. Franklin Street Advisors Inc. NC now owns 217,411 shares of the biopharmaceutical company’s stock valued at $19,971,000 after buying an additional 12,758 shares in the last quarter. Capital Asset Advisory Services LLC purchased a new position in Gilead Sciences during the first quarter valued at approximately $1,690,000. Banced Corp raised its position in Gilead Sciences by 20.5% in the first quarter. Banced Corp now owns 15,179 shares of the biopharmaceutical company’s stock valued at $1,395,000 after buying an additional 2,583 shares in the last quarter. Webster Bank N. A. raised its position in Gilead Sciences by 6.8% in the first quarter. Webster Bank N. A. now owns 26,811 shares of the biopharmaceutical company’s stock valued at $2,463,000 after buying an additional 1,707 shares in the last quarter. Finally, Searle & CO. raised its position in Gilead Sciences by 1.5% in the first quarter. Searle & CO. now owns 14,570 shares of the biopharmaceutical company’s stock valued at $1,371,000 after buying an additional 220 shares in the last quarter. 77.94% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on GILD shares. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $108.00 price objective on shares of Gilead Sciences in a research note on Monday, August 15th. Jefferies Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $76.89 to $91.00 in a research note on Tuesday, September 6th. Morgan Stanley reissued a “hold” rating and set a $103.00 target price on shares of Gilead Sciences in a research note on Wednesday, June 15th. Berenberg Bank initiated coverage on shares of Gilead Sciences in a research note on Thursday, September 22nd. They set a “buy” rating for the company. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Sunday, July 10th. Eleven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $104.34.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.